News
-
-
-
PRESS RELEASE
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines, adding rare immunology disease medicines to its portfolio. The acquisition includes Ayvakit/Ayvakyt for systemic mastocytosis (SM) and elenestinib for SM, enhancing Sanofi's immunology pipeline -
-
-
-
-
-
-